RxDoctor Payments Data

Makondo Shimukowa, MD

Infectious Disease · Delmar, DENPI 1730389982

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $416 and has fallen 58.6% since, to $172 in 2025.

$1,661in general payments, 2019–2025

Across 75 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$350
  • Gilead$340
  • Merck$220
  • Viiv Healthcare Company$183
  • Johnson & Johnson$127
  • Ferring Pharmaceuticals Inc.$85
  • plus $356 from 12 others

What the payments were for

  • Food & beverage$1,52792%
  • Education$1338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,661 in reported general payments places this provider in the 70th percentile of 28 infectious disease providers in Delaware.

See all infectious disease providers in Delaware

Medicare billing

Part B allowed, 2024
$194,118
Medicare patients
524
Services billed
2,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin36$65,248
CeftriaxoneCeftriaxone Sodium68$25,725
ErtapenemErtapenem Sodium21$10,538
Vancomycin Hcl45$9,307
Cefepime Hcl29$5,339
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium14$3,011
Cefazolin Sodium13$1,033
Doxycycline Hyclate22$503
Cephalexin12$442
Cefdinir16$435
Azithromycin13$305
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$103
Amoxicillin12$98
Fluconazole11$62
Penicillin V Potassium11$45

Paid to pharmacies, not to this prescriber.

Other infectious disease in Delmar

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →